Name:	WIDES
Enrolment No:	UNIVERSITY OF TOMORROW

UPES

End Semester Examination, December 2024

Course: GMP and GLP Semester:3rd

Program: BTech BIOMEDICAL ENGINEERING and BIOTECHNOLOGY

Duration: 3 Hours

Course Code: HSBE4025 Max. Marks: 100

Instructions: Attempt all questions

S. No.	Section A	Marks	COs
	Short answer questions/ MCQ/T&F		
	(20Qx1.5M=30 Marks)		
Q 1	Which regulatory guideline focuses on stability testing for drug	1.5	CO1
	products?		
	a) ICH Q1A		
	b) ICH Q8		
	c) FDA Part 11		
	d) GMP Annex 11		
Q 2	In GMP, which document provides details of the manufacturing	1.5	CO1
	process for a product?		
	a) Master Batch Record		
	b) Risk Management Report		
	c) Quality Manual		
	d) Site Master File		
Q 3	Which authority oversees drug approval in Europe?	1.5	CO1
	a) Food and Drug Administration (FDA)		
	b) European Medicines Agency (EMA)		
	c) World Health Organization (WHO)		
	d) Medicines and Healthcare products Regulatory Agency		
	(MHRA)		
Q 4	Which phase of clinical trials is primarily concerned with	1.5	CO2
	determining a drug's efficacy?		
	a) Phase I		
	b) Phase II		
	c) Phase III		
	d) Phase IV		
Q 5	Which term describes practices to maintain equipment cleanliness	1.5	CO2
	in GMP facilities?		
	a) Sterilization		

		I	
	b) Calibration		
	c) Quality Control		
	d) Validation		
Q 6	In QBD, "Critical Quality Attributes" refer to:	1.5	CO3
	a) Essential product characteristics		
	b) Operational guidelines		
	c) Marketing attributes		
	d) Employee responsibilities		
Q 7	Which ICH guideline primarily focuses on risk management in	1.5	CO3
	drug development?		
	a) Q8		
	b) Q9		
	c) Q10		
	d) Q1		
Q 8	GMP requirements for training are outlined in:	1.5	CO2
	a) ICH Q9		
	b) WHO TRS 961		
	c) FDA 21 CFR Part 11		
	d) ISO 9001		
Q 9	Which phase of drug development is primarily concerned with	1.5	CO2
	ensuring safety in humans?		
	a) Preclinical studies		
	b) Clinical Phase I		
	c) Clinical Phase II		
	d) Post-marketing surveillance		
Q 10	In GMP, which of the following is critical for maintaining product	1.5	CO3
	quality?		
	a) Automated marketing		
	b) Facility cleanliness		
	c) Increased production speed		
	d) Flexible documentation		
Q 11	The role of national and international regulatory authorities is to:	1.5	CO3
	a) Oversee research funding		
	b) Enforce product quality and safety standards		
	c) Create product marketing plans		
	d) Organize training for pharmaceutical employees		
Q 12	Which term describes practices to maintain equipment cleanliness	1.5	CO3
	in GMP facilities?		
	a) Sterilization		
	b) Calibration		
	c) Quality Control		
	d) Validation		
Q 13	Quality by Design (QBD) is only used in the pharmaceutical	1.5	CO2
	industry. (True Or False)		

Q 14	GMP regulations are consistent worldwide. (True or False)	1.5	CO3
Q 15	What is the significance of ICH Q9 in pharmaceutical	1.5	CO2
	manufacturing?		
Q 16	Design of Experiment (DOE) is only applicable to chemical	1.5	CO3
	testing. (True or False)		
Q 17	Define "Pharmaceutical Jurisprudence."	1.5	CO2
Q 18	GLP and GMP compliance are optional for clinical trials. (True or	1.5	CO1
	False)		
Q 19	What is meant by "analytical method validation"?	1.5	CO3
Q 20	Name two advantages of implementing QBD in product	1.5	CO1
	development.		
	Section B		
	(4Qx5M=20 Marks)		
Q 1	Discuss the role of ICH guidelines in harmonizing drug quality	5	CO2
	standards globally.		
Q 2	Describe the significance of batch records and how they contribute	5	CO2
~ ~	to GMP compliance.		
Q 3	List the application of Design of Experiment (DOE) in process	5	CO1
	optimization. (2.5 Marks)		
	Give an example of how DOE helps with quality control. (2.5		
	Marks)		
Q 4	Explain ethical importance of GLP in preclinical research and its	5	CO3
	impact on public health.		
	Section C		
	(2Qx15M=30 Marks)		
Q 1	Describe the principles of Quality by Design (QBD) and its	15	CO3
	application throughout the product lifecycle. (5 Marks)		
	Discuss how QBD can reduce risks in product quality and		
	contribute to regulatory compliance. (5 Marks)		
	Include examples of QBD tools and techniques, such as DOE. (5		
	Marks)		
Q2	Compare and contrast Good Laboratory Practice (GLP) and Good	15	CO2
	Manufacturing Practice (GMP). (5 Marks)		
	Describe their roles in different stages of drug development, the		
	specific requirements of each, and their impact on ensuring drug		
	quality and safety. (10 Marks)		
	Section D		
0.1	(2Qx10M=20 Marks)	10	CO2
Q 1	Discuss the role of regulatory authorities, such as the FDA and	10	CO2
	EMA, in overseeing drug safety, efficacy, and quality. (5 Marks)		

	Explain how these agencies contribute to protecting public health		
	and the differences in their regulatory approaches, if any. (5		
	Marks)		
Q2	Explain the purpose and process of analytical method validation in	10	CO3
	drug development. (5 Marks)		
	Identify the essential parameters requiring validation and		
	demonstrate how validation processes enhance quality assurance		
	and facilitate regulatory approval. (5 Marks)		